Company Of The Day: Roche Holdings

-5.04%
Downside
26.29
Market
24.96
Trefis
NWSA: News logo
NWSA
News

What?

Roche Holdings (OTCMKTS: RHHBY) Q3 2022 revenue declined 6% to CHF 14.74 billion ($14.8 billion).

Why?

Relevant Articles
  1. Can A New Model Y Challenger Get Nio Stock Back On Track?
  2. Which Is A Better Pick – Norfolk Southern Or Snowflake Stock?
  3. Up 4% This Year, Will Q1 Results Drive Lowe’s Stock Higher?
  4. Up 7% YTD, What To Expect From NASDAQ Stock?
  5. Is Deere Stock Fully Valued At $400?
  6. Up 3x In A Week Will Novavax Stock Continue To See Higher Levels?

A decline in demand for Covid-19 diagnostics and treatments outweighed the gains that the company made with its hemophilia and multiple sclerosis drugs.

So What?

Roche stock was down by almost 1.5% in early trading on Tuesday although it recovered later in the day.

See Our Complete Analysis For Roche

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns Oct 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 RHHBY Return 1% -20% 44%
 S&P 500 Return 4% -22% 66%
 Trefis Multi-Strategy Portfolio 3% -24% 201%

[1] Month-to-date and year-to-date as of 10/19/2022
[2] Cumulative total returns since the end of 2016

 

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates